Research programme: neuropsychiatric therapeutics - GeNeuro
Latest Information Update: 28 Nov 2022
Price :
$50 *
At a glance
- Originator GeNeuro
- Class Monoclonal antibodies; Neuropsychotherapeutics
- Mechanism of Action Viral envelope protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Psychotic disorders
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in Psychotic-disorders in Switzerland (Parenteral)
- 08 Oct 2018 Preclinical development in Psychotic disorders is ongoing in Switzerland (Parenteral) (GeNeuro pipeline, October 2018)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Psychotic-disorders in Switzerland